Dear Colleagues: Several weeks ago I posted a notice of warning concerning the use of Lamotrigine(Lamictal) in breastfeeding women. It concerned the rather high incidence of Stevens-Johnson syndrome in children using this product (one in fifteen). It was apparently posted by the Glaxo company who makes the product. After discussing this with my colleague Frank Nice, his sources at the FDA suggest that the true incidence of dangerous rashes is probably much less around 0.5% and that this may be dose related, only occurring at higher doses(>3mg/kg). Fortunately, the published levels in milk would only provide about 2-5 mg per day to the infant which is probably far too low to induce this syndrome. It is their contention(FDA), that the dose in milk would not approach this high dose, and I concur. While I think we should be somewhat cautious using Lamotrigine in breastfeeding women, always observing for rashs, I concur with their suggestion that the risk of Stevens Johnson syndrome is probably less probable than I was led to believe. So I stand corrected. Thanks to Frank for his help on this matter. Regards Tom Hale, Ph.D. *********************************************** The LACTNET mailing list is powered by L-Soft's renowned LISTSERV(R) list management software together with L-Soft's LSMTP(TM) mailer for lightning fast mail delivery. For more information, go to: http://www.lsoft.com/LISTSERV-powered.html